Azole compounds and terbinafine have been extensively used to treat tinea pedis and tinea unguium, which are mainly caused by Trichophyton rubrum and T. interdigitale. Isolates with reduced sensitivity to azoles and terbinafine have emerged in several countries, such as Switzerland, Denmark and India. [1][2][3][4][5] So far, terbinafine resistance was always associated with a non-synonymous point mutation in the squalene epoxidase (SQLE) gene of T rubrum and T interdigitale (Leu 393 , Phe 397 , Phe 415 and His 440 ), the first two positions being predominant.One particular terbinafine resistant isolate, TIMM20092, 1 also showed reduced sensitivity to azoles. This strain was isolated from a patient with tinea pedis insensitive to standard systemic and topical terbinafine and itraconazole (ITC) treatments. Sequencing of the Cyp51A gene encoding the lanosterol 14α-demethylase targeted by azole compounds revealed no non-synonymous point mutations in TIMM20092, but the expression of two genes (TruMDR2 and TruMDR3) encoding multidrug transporters of the ABC family were significantly up-regulated. 6TruMDR3 was shown to confer resistance to fluconazole, ITC, ketoconazole, miconazole and VRC when overexpressed in the yeast